男友太凶猛1v1高h,大地资源在线资源免费观看 ,人妻少妇精品视频二区,极度sm残忍bdsm变态

Global EditionASIA 中文雙語Fran?ais
China
Home / China / Health

Medical experts call for greater access to rare disease treatments

By ZHOU WENTING in Shanghai | chinadaily.com.cn | Updated: 2020-06-05 14:08
Share
Share - WeChat

Some of China's leading medical experts have suggested establishing a "1+4" multiparty payment mechanism to make exorbitant treatments for rare diseases available to more patients.

The "one" refers to the basic national medical insurance, meaning that drugs for rare diseases shall be included in the country's list of drugs that can be partially reimbursed, they said.

There have been such pilot programs in some provinces in recent years but the practices throughout all the provincial-level regions should be uniform, said Ding Jie, a national political advisor who was among those who made the suggestion.

"The 'four' refers to: the setting up of special relief programs at both national and provincial governments, integrating social resources, introducing commercial insurance and having individuals pay for part of the medical bills," said Ding during a live broadcast on Wednesday about increasing the accessibility and affordability of rare disease therapies for patients.

She said the suggestion was a result of extensive discussions with experts in medicine, public health, medical insurance, law and economics.

Wang Lin, a member of the expert committee of diagnosis, treatment and security of rare diseases with the National Health Commission and vice director of the rare disease branch of the Beijing Medical Association, said that Zhejiang province has already set up a special relief program at the provincial level to "help patients with the payment of expensive therapies as much as possible while relieving the pressure of medical insurance funds".

Each person in the province paid 2 yuan ($0.28) every year to the relief program, according to Wang.

She added that the country has made progress over the past two years in terms of accelerating the introduction of innovative rare disease drugs to the domestic market to increase drug availability.

The latest examples include the first effective drug for Fabry, a lethal rare malady which is caused by a deficiency of a particular enzyme. The drug was made available to Chinese patients last month.

Another drug for mucopolysaccharidosis, a rare metabolic disorder caused by the absence or malfunction of lysosomal enzymes, was approved by the National Medical Products Administration earlier this week.

Experts have also pointed out that families with rare disease patients accounted for a large number of those who were dragged into poverty due to illness.

"Helping such families through various means also contributes to the country's efforts in poverty alleviation," Ding said.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
 
主站蜘蛛池模板: 德庆县| 宝鸡市| 布拖县| 平安县| 迭部县| 万全县| 屏东市| 蒙城县| 邛崃市| 海伦市| 宜宾县| 六安市| 新密市| 敦煌市| 榆社县| 昌图县| 太仆寺旗| 大洼县| 涿州市| 济南市| 叶城县| 三明市| 邢台市| 临沭县| 三门县| 武邑县| 滕州市| 乌鲁木齐市| 松桃| 襄樊市| 满洲里市| 芜湖市| 玉屏| 融水| 大庆市| 罗城| 宁陕县| 枣阳市| 穆棱市| 孝昌县| 涟源市|